Premium
Comparison of two 3‐day Helicobacter pylori eradication regimens with a standard 1‐week regimen
Author(s) -
C. E. Grimley,
Alan F. Penny,
M O'Sullivan,
M Shebani,
J R Lismore,
Ray Cross,
R. C. Illing,
Duncan E. Loft,
Chuka U. Nwokolo
Publication year - 1999
Publication title -
alimentary pharmacology and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.308
H-Index - 177
eISSN - 1365-2036
pISSN - 0269-2813
DOI - 10.1046/j.1365-2036.1999.00574.x
Subject(s) - medicine , clarithromycin , omeprazole , helicobacter pylori , gastroenterology , metronidazole , lansoprazole , regimen , rapid urease test , amoxicillin , breath test , antibiotics , gastritis , microbiology and biotechnology , biology
Background : The duration of Helicobacter pylori eradication regimens has decreased to 1 week with cure rates of over 90%. This can be attributed to the use of triple drug regimens including potent inhibitors of gastric acid secretion and clarithromycin. There is no theoretical reason why shorter regimens should not be possible. Aim : To compare two 3‐day, low‐dose, twice daily regimens with 1 week of omeprazole 20 mg b.d., clarithromycin 250 mg b.d., and metronidazole 400 mg b.d. (OCM) Methods : Outpatients referred for gastroscopy were screened by biopsy urease test. H. pylori ‐positive patients were randomized to receive either lansoprazole 30 mg b.d., tri‐potassium dicitrato bismuthate one tablet b.d., clarithromycin 250 mg b.d., and amoxycillin 1 g b.d. for 3 days (LTdbCA), or ranitidine bismuth citrate 400 mg b.d., clarithromycin 250 mg b.d. and amoxycillin 1 g b.d. for 3 days (RbcCA) or omeprazole 20 mg b.d., clarithromycin 250 mg b.d. and metronidazole 400 mg b.d. for 1 week (OCM). They were not pre‐treated with a gastric acid inhibitor. After 8 weeks, H. pylori status was assessed by 13 C urea breath test. Results : 974 out of 1114 patients referred for gastroscopy were screened by biopsy urease test. 140 patients were not screened either because they were anticoagulated or for technical reasons. 334 patients were H. pylori‐ positive: 154 were excluded mostly because of allergy to penicillin and personal reasons but 180 were randomized to treatment All regimens were well tolerated. For LTdbCA ( n =60), RbcCA ( n =59), and OCM ( n =61) the H. pylori cure rates (95% CI) were 23% (12–34), 14% (5–23) and 87% (79–95), respectively, using intention‐to‐treat analysis and 25% (14–36), 15% (6–24) and 88% (80–96), respectively, if analysed per protocol. OCM was significantly superior to LTdbCA and RbcCA ( P < 0.001) but there was no significant difference between regimens LTdbCA and RbcCA. Conclusions : OCM is an extremely effective H. pylori eradication regimen. The 3‐day regimens tested both have poor cure rates. Pre‐treatment with a proton pump inhibitor, higher doses or more frequent dosing may be necessary to increase the cure rate of short duration regimens. However, this could make them less acceptable than the H. pylori eradication regimens currently available.